Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)

Study Identifier
CMO-US-URO-0506
CT.gov Identifier
NCT03043287
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Bladder Disorder - Overactive Bladder
    • Study Drug
  • onabotulinumtoxinA
    • Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Patient with documented idiopathic OAB diagnosis * Patient was treated with 100-200U of BOTOX® for OAB * Urodynamics assessment within prior to first BOTOX® injection.
    Exclusion Criteria:
    * Patient had received botulinum toxin formulations other than BOTOX® in the bladder * Patient had symptoms of OAB associated with a neurological condition (eg, spinal cord injury, multiple sclerosis, cerebrovascular accident, Alzheimer's disease, Parkinson's disease, etc).

    Protocol Summary

    This study is a retrospective chart review of patients treated with onabotulinumtoxinA (BOTOX®) for idiopathic overactive bladder (OAB) and will determine voiding efficiency (VE) cutoff ratios that predict post-procedure urinary retention requiring catheterization.

    Study Locations

    Location
    Status
    Location
    Regional Urology
    Shreveport, Louisiana, United States, 71106
    Status
    Not applicable
    Location
    Chesapeake Urology Associates, LLC
    Baltimore, Maryland, United States, 21208
    Status
    Not applicable
    Location
    Virginia Urology
    Richmond, Virginia, United States, 23235
    Status
    Not applicable